NASDAQ:PASG Passage Bio (PASG) Stock Price, News & Analysis → Breaking News: Elon Musk Invents New Type of A.I. (Shocking) (From InvestorPlace) (Ad) Free PASG Stock Alerts $1.32 -0.02 (-1.49%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$1.32▼$1.3950-Day Range$1.14▼$1.5852-Week Range$0.58▼$1.79Volume38,644 shsAverage Volume116,002 shsMarket Capitalization$81.37 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Passage Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside581.8% Upside$9.00 Price TargetShort InterestBearish4.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.83Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.13) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.29 out of 5 starsMedical Sector530th out of 914 stocksBiological Products, Except Diagnostic Industry79th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingPassage Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePassage Bio has only been the subject of 1 research reports in the past 90 days.Read more about Passage Bio's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.28% of the float of Passage Bio has been sold short.Short Interest Ratio / Days to CoverPassage Bio has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Passage Bio has recently increased by 0.57%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPassage Bio does not currently pay a dividend.Dividend GrowthPassage Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PASG. Previous Next 2.7 News and Social Media Coverage News SentimentPassage Bio has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Passage Bio this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for PASG on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Passage Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Passage Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Passage Bio is held by insiders.Percentage Held by Institutions53.48% of the stock of Passage Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Passage Bio's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Passage Bio are expected to grow in the coming year, from ($1.13) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Passage Bio is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Passage Bio is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPassage Bio has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Passage Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… About Passage Bio Stock (NASDAQ:PASG)Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More PASG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PASG Stock News HeadlinesMay 19 at 3:32 AM | americanbankingnews.comPassage Bio (NASDAQ:PASG) PT Lowered to $13.00 at Canaccord Genuity GroupMay 16 at 6:56 AM | americanbankingnews.comEquities Analysts Issue Forecasts for Passage Bio, Inc.'s Q2 2024 Earnings (NASDAQ:PASG)May 16 at 3:02 AM | americanbankingnews.comPassage Bio, Inc. (NASDAQ:PASG) to Post Q1 2025 Earnings of ($0.20) Per Share, Wedbush ForecastsMay 15, 2024 | markets.businessinsider.comOptimistic Outlook for Passage Bio Amid Clinical and Financial Progress: Maintains Buy RatingMay 15, 2024 | msn.comPassage Bio Reports Promising Interim Data in FTD-GRN Treatment TrialMay 14, 2024 | investorplace.comPASG Stock Earnings: Passage Bio Beats EPS for Q1 2024May 14, 2024 | globenewswire.comPassage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business HighlightsMay 11, 2024 | americanbankingnews.comPassage Bio (NASDAQ:PASG) Trading Up 0.7%April 22, 2024 | finance.yahoo.comPassage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 22, 2024 | globenewswire.comPassage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitMarch 20, 2024 | finance.yahoo.comPASG Apr 2024 7.500 callMarch 16, 2024 | finance.yahoo.comPASG Apr 2024 5.000 callMarch 6, 2024 | investorplace.comPASG Stock Earnings: Passage Bio Beats EPS for Q4 2023March 5, 2024 | finance.yahoo.comPassage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship ProgramMarch 4, 2024 | globenewswire.comPassage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business HighlightsMarch 3, 2024 | msn.comPassage Bio to Showcase Advancements at Major Health Care ConferencesFebruary 27, 2024 | globenewswire.comPassage Bio to Participate in Upcoming Investor ConferencesFebruary 20, 2024 | investing.comPassage Bio Inc (PASG)February 16, 2024 | investing.comPASG/USD - Passage US DollarFebruary 12, 2024 | finance.yahoo.comWe Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth CarefullyFebruary 2, 2024 | msn.comPassage Bio CEO to Address Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceJanuary 31, 2024 | finance.yahoo.comPassage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceDecember 21, 2023 | benzinga.comPassage Bio Stock (NASDAQ:PASG) Dividends: History, Yield and DatesDecember 20, 2023 | msn.comNeurology-Focused Passage Bio Reveals Initial Data From Dementia Study, Outlines Strategic PrioritiesDecember 20, 2023 | markets.businessinsider.comPassage Bio Announces Initial Clinical Data From Phase 1/2 UpliFT-D Trial On PBFT02See More Headlines Company Calendar Last Earnings3/04/2024Today5/19/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PASG CUSIPN/A CIK1787297 Webwww.passagebio.com Phone267-866-0311FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$13.00 Low Stock Price Target$5.00 Potential Upside/Downside+581.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-68.53% Return on Assets-51.64% Debt Debt-to-Equity RatioN/A Current Ratio8.43 Quick Ratio7.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.70 per share Price / Book0.78Miscellaneous Outstanding Shares61,640,000Free Float58,990,000Market Cap$81.36 million OptionableOptionable Beta1.28 Key ExecutivesDr. William Chou M.D. (Age 50)President, CEO & Director Comp: $945.73kEden FucciSenior Vice President of Technical OperationsDr. Sue Browne Ph.D.Senior Vice President of Research & DevelopmentDr. Karl Whitney Ph.D.Senior Vice President of Global Regulatory AffairsKey CompetitorsCurisNASDAQ:CRISAlloVirNASDAQ:ALVRProtalix BioTherapeuticsNYSE:PLXAthira PharmaNASDAQ:ATHAOutlook TherapeuticsNASDAQ:OTLKView All CompetitorsInsiders & InstitutionsAffinity Asset Advisors LLCBought 264,266 shares on 5/15/2024Ownership: 0.429%Vanguard Group Inc.Bought 52,656 shares on 5/10/2024Ownership: 3.362%Acadian Asset Management LLCBought 356,593 shares on 5/10/2024Ownership: 1.560%Mark S FormanSold 1,638 sharesTotal: $1,588.86 ($0.97/share)Kathleen BorthwickSold 1,470 sharesTotal: $1,425.90 ($0.97/share)View All Insider TransactionsView All Institutional Transactions PASG Stock Analysis - Frequently Asked Questions Should I buy or sell Passage Bio stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PASG shares. View PASG analyst ratings or view top-rated stocks. What is Passage Bio's stock price target for 2024? 3 brokerages have issued 1 year price objectives for Passage Bio's shares. Their PASG share price targets range from $5.00 to $13.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 581.8% from the stock's current price. View analysts price targets for PASG or view top-rated stocks among Wall Street analysts. How have PASG shares performed in 2024? Passage Bio's stock was trading at $1.01 at the beginning of 2024. Since then, PASG shares have increased by 30.7% and is now trading at $1.32. View the best growth stocks for 2024 here. When is Passage Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our PASG earnings forecast. How were Passage Bio's earnings last quarter? Passage Bio, Inc. (NASDAQ:PASG) released its quarterly earnings data on Monday, March, 4th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.11. What other stocks do shareholders of Passage Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include Alector (ALEC), NVIDIA (NVDA), Advanced Micro Devices (AMD), DocuSign (DOCU), Intel (INTC), Alteryx (AYX), Gossamer Bio (GOSS), JD.com (JD), Micron Technology (MU) and Black Diamond Therapeutics (BDTX). When did Passage Bio IPO? Passage Bio (PASG) raised $126 million in an IPO on Friday, February 28th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Chardan was co-manager. Who are Passage Bio's major shareholders? Passage Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.36%), Acadian Asset Management LLC (1.56%) and Affinity Asset Advisors LLC (0.43%). Insiders that own company stock include Alexandros Fotopoulos, Bruce A Goldsmith, Kathleen Borthwick, Mark S Forman, Orbimed Advisors Llc, Richard Steven Morris, Sandip Kapadia and Simona King. View institutional ownership trends. How do I buy shares of Passage Bio? Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PASG) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceMost important medical advance in 100 yearsThe Oxford ClubCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin AnalyticsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
